PMCF Strategy: Turning Post-Market Clinical Data into a Competitive Advantage
A strong PMCF strategy does more than keep your CE certificate. It plans the clinical evidence your devices need across markets and years, so every survey, registry and study also supports new claims, tenders, reimbursement and better products.
Why your devices need a PMCF strategy, not just a PMCF plan
Most manufacturers write a PMCF plan for each device because EU MDR requires it. Far fewer have a PMCF strategy: a portfolio-level view of what clinical evidence the business needs, in which markets, and when.
Without one, PMCF becomes a yearly scramble: generic surveys, low-quality data and Notified Body findings. With one, the same budget produces evidence that keeps certificates safe, supports new indications and wins business with hospitals, payers and distributors.
Our 5-step PMCF strategy framework
How we build a PMCF strategy that satisfies regulators and serves the business.
What a good PMCF strategy delivers beyond compliance
Who does what in PMCF under EU MDR
The manufacturer owns PMCF. Others check it, act on it or support it.
| Role | Responsibility in PMCF |
|---|---|
| Manufacturer | Plans, runs and reports PMCF; updates CER, risk file, PSUR and SSCP; acts on findings |
| Notified Body | Assesses the PMCF plan, evaluation report and PSUR during certification and surveillance |
| Competent authorities | Monitor vigilance and market surveillance; can request information and corrective action |
| Expert panels | Give opinions on the clinical evaluation of certain high-risk devices |
| Investigators and sites | Collect PMCF study data under the protocol and good clinical practice |
| CRO partner | Designs and runs PMCF activities and analyses the data on the manufacturer’s behalf |
PMCF and post-market clinical evidence in the EU, USA and UK
The EU requires proactive PMCF for nearly all devices, while the FDA targets specific high-risk devices. A global strategy plans one evidence programme for all of them.
| Topic | European Union | United States | Great Britain |
|---|---|---|---|
| Approach | Proactive PMCF for all classes, or a justification | Targeted: required only in defined cases | PMS plan and reporting for all devices |
| Main instruments | PMCF plan and evaluation report, PSUR, SSCP | Section 522 postmarket surveillance; PMA post-approval studies | GB post-market surveillance rules, PSUR or PMS report |
| Who triggers it | Manufacturer, reviewed by the Notified Body | FDA orders it for specific devices | Manufacturer, overseen by the MHRA |
| Adverse event reporting | MDR Articles 87–92 | 21 CFR 803 medical device reporting | GB vigilance and serious incident reporting |
How the PMCF strategy changes with your device situation
There is no single PMCF approach. We tailor it to where your device stands.
| Device situation | Typical evidence gap | Strategic focus |
|---|---|---|
| New MDR device | Limited long-term and real-world data | Targeted studies on residual risks and claims |
| Legacy MDD device moving to MDR | Old or missing clinical data | Close gaps under MDCG 2020-6 using registries, literature and focused studies |
| Well-established technology | Little device-specific data, strong state of the art | Proportionate, mainly general methods with clear justification |
| Innovative or Class III device | High uncertainty and close regulator attention | Prospective PMCF studies, yearly reporting and SSCP updates |
| Device family or portfolio | Duplicated, inconsistent PMCF | Shared registries and studies covering several devices |
Where is your PMCF today?
How REGHELPS supports your PMCF strategy
PMCF strategy FAQs
What is a PMCF strategy?
A PMCF strategy is the long-term plan for how you will generate post-market clinical evidence across your product portfolio and its lifecycle. It sets priorities, chooses methods, links data sources and decides how results will be used for compliance, product development and market access.
How is a PMCF strategy different from a PMCF plan?
The PMCF plan is a regulatory document for one device or device family, following MDR Annex XIV Part B and MDCG 2020-7. The strategy sits above it: it decides what evidence the business needs across devices, markets and years, and makes sure every PMCF plan supports that direction.
Does the FDA require PMCF?
The FDA does not use the term PMCF. It can order Section 522 postmarket surveillance studies for certain Class II and III devices, and it can require post-approval studies as a condition of PMA approval. Medical device reporting under 21 CFR 803 applies to all devices. A global strategy aligns these with EU PMCF so one dataset serves several regulators.
How can PMCF create commercial value?
Well-designed PMCF can support new or broader claims, provide evidence for tenders, reimbursement and health technology assessment, speed up Notified Body reviews, show advantages over competitors and feed design improvements into the next device generation.
How should legacy MDD devices approach PMCF?
Legacy devices moving to MDR often have gaps in clinical evidence. MDCG 2020-6 explains what sufficient clinical evidence means for them. A focused PMCF strategy uses registries, literature, surveys and targeted studies to close those gaps before and after MDR certification.
How often should a PMCF strategy be reviewed?
At least whenever the CER, PSUR or SSCP is updated, and whenever new risks, design changes, new markets or new claims appear. For Class III and implantable devices this means at least once a year.
Ready to make PMCF work harder for your business?
Tell us about your devices and markets using the form below and we'll suggest a PMCF strategy and roadmap.
